Patents by Inventor Michael Scott Kinch

Michael Scott Kinch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EphA2 monoclonal antibodies and methods of making and using same
    Patent number: 7402298
    Abstract: The invention provides a monoclonal antibody, a fragment thereof, or a molecular complex thereof that binds to an extracellular domain of an EphA2 receptor molecule, wherein binding of the monoclonal antibody or fragment thereof to the EphA2 receptor molecule present in the membrane of a cancer cell favorably alters activity of the EphA2 receptor molecule. The invention further relates to methods of making and using the monoclonal antibodies, fragments, and molecular complexes regarding the same. The monoclonal antibodies of the present invention target the extracellular domain of EphA2 and operate to redirect the function of EphA2 to selectively block the growth and invasiveness of metastatic cells. The invention thus makes possible therapeutic strategies that optimally target metastatic cells while preventing collateral damage to normal tissues.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: July 22, 2008
    Assignees: Purdue Research Foundation, SmithKline Beecham Corporation
    Inventors: Michael Scott Kinch, Kelly Carles-Kinch, Katherine E Kilpatrick
  • EphA2 monoclonal antibodies and methods of making and using same
    Patent number: 7101976
    Abstract: The invention provides a monoclonal antibody, a fragment thereof, or a molecular complex thereof that binds to an extracellular domain of an EphA2 receptor molecule, wherein binding of the monoclonal antibody or fragment thereof to the EphA2 receptor molecule present in the membrane of a cancer cell favorably alters activity of the EphA2 receptor molecule. The invention further relates to methods of making and using the monoclonal antibodies, fragments, and molecular complexes regarding the same. The monoclonal antibodies of the present invention target the extracellular domain of EphA2 and operate to redirect the function of EphA2 to selectively block the growth and invasiveness of metastatic cells. The invention thus makes possible therapeutic strategies that optimally target metastatic cells while preventing collateral damage to normal tissues.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: September 5, 2006
    Assignees: Purdue Research Foundation, SmithKline Beecham Corporation
    Inventors: Katherine E Kilpatrick, Michael Scott Kinch, Kelly Carles-Kinch